Cystic Fibrosis Triplet Could Unblock EU Reimbursement Impasse
Executive Summary
Cystic fibrosis specialist Vertex remains at loggerheads with HTAs in England and France over its product pricing, but hopes its triplet regimes can eventually break the impasse.